R
Rachel Lanel
Researcher at French Institute of Health and Medical Research
Publications - 5
Citations - 366
Rachel Lanel is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Osteosarcoma & Tumor progression. The author has an hindex of 4, co-authored 5 publications receiving 271 citations. Previous affiliations of Rachel Lanel include University of Nantes.
Papers
More filters
Journal ArticleDOI
Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment
Aude I. Segaliny,Amel Mohamadi,Amel Mohamadi,Blandine Dizier,Blandine Dizier,Anna Lokajczyk,Anna Lokajczyk,Régis Brion,Régis Brion,Rachel Lanel,Rachel Lanel,Jérôme Amiaud,Jérôme Amiaud,Céline Charrier,Céline Charrier,Catherine Boisson-Vidal,Catherine Boisson-Vidal,Dominique Heymann,Dominique Heymann +18 more
TL;DR: It is demonstrated that IL‐34 is expressed by osteosarcoma cells, is regulated by TNF‐α, IL‐1β, and contributes to osteosARcoma growth by increasing the neo‐angiogenesis and the recruitment of M2 macrophages.
Journal ArticleDOI
Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma
Clotilde Dumars,Jean-Michel Ngyuen,Aurelie Gaultier,Rachel Lanel,Nadège Corradini,François Gouin,Dominique Heymann,Marie-Françoise Heymann +7 more
TL;DR: The present work aims to better characterize the tumor microenvironment in OS in order to identify new therapeutic targets relating to metastatic process, and found TAMs are associated with better overall survival and a dysregulation of M1/M2 polarized-macrophages in favor of M 1 subtype was observed in non-metastatic OS.
Journal ArticleDOI
NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate.
Bérengère Gobin,Bérengère Gobin,Séverine Battaglia,Séverine Battaglia,Rachel Lanel,Rachel Lanel,Julie Chesneau,Julie Chesneau,Jérôme Amiaud,Jérôme Amiaud,Françoise Rédini,Françoise Rédini,Benjamin Ory,Benjamin Ory,Dominique Heymann,Dominique Heymann +15 more
TL;DR: The results of the present work show that NVP-BEZ235 exhibits therapeutic interest in osteosarcoma and may be a promising adjuvant drug for bone sarcomas.
Journal ArticleDOI
BYL719, a new α‐specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma
Bérengère Gobin,Bérengère Gobin,Marc Baud' Huin,Marc Baud' Huin,Francois Lamoureux,Francois Lamoureux,Benjamin Ory,Benjamin Ory,Céline Charrier,Céline Charrier,Rachel Lanel,Rachel Lanel,Séverine Battaglia,Séverine Battaglia,Françoise Rédini,Frédéric Lézot,Frédéric Lézot,Frédéric Blanchard,Frédéric Blanchard,Dominique Heymann +19 more
TL;DR: Overall, the present work shows that BYL719 is a promising drug in either a single or multidrug approach to curing bone sarcoma.